Theravance Confirms Favorable Ruling from FDA Panel on VIBATIV

Theravance Inc. THRX today announced a favorable outcome of the Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S. FDA meeting on VIBATIV(R) (telavancin) for the treatment of nosocomial pneumonia (NP) due to susceptible isolates of Gram-positive microorganisms.